Sarclisa Combination Shows Positive Results in Patients With Relapsed Multiple Myeloma

by | May 18, 2022 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Latest results of the phase 3 IKEMA trial demonstrate the longest median progression-free survival on a proteasome inhibitor backbone in this population, Sanofi says.
Read More

Submit a Comment